Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A clinician-reviewed deep dive into the emerging mechanisms driving NAFLD and MASLD, covering gut-liver axis dysfunction, lipotoxicity, mitochondrial failure, and the newest therapeutic targets backed by primary trial data.
Read clinical reviewNAFLD affects roughly 38% of adults worldwide under the newer MASLD criteria. This evidence-based overview covers global prevalence data, regional variation, risk factor trends, and what the 2023 nomenclature change means for clinicians and patients.
Read clinical reviewA clinical history of NAFLD and MASLD treatment from the 1980s to today, covering lifestyle interventions, vitamin E, pioglitazone, and the first FDA-approved therapy resmetirom, with primary-source citations throughout.
Read clinical reviewA physician-reviewed deep dive into the most contested clinical questions in NAFLD and MASLD: naming debates, screening thresholds, fibrosis staging, drug approvals, and more. Inline citations to PubMed, FDA, and society guidelines throughout.
Read clinical reviewHow NAFLD and MASLD differ between children and adults in histology, risk factors, diagnosis, and treatment. Evidence-based guide with primary citations.
Read clinical reviewA comprehensive clinical review of racial and ethnic disparities in NAFLD / MASLD prevalence, severity, genetics, and treatment access, with primary-source citations and physician-reviewed guidance.
Read clinical reviewA comprehensive clinical guide to the rare and atypical presentations of NAFLD and MASLD, including lean MASLD, pediatric disease, cryptogenic cirrhosis, cardiac involvement, and more, with primary-source citations throughout.
Read clinical reviewA detailed, clinician-reviewed breakdown of the socioeconomic burden of NAFLD/MASLD: healthcare costs, lost productivity, disability, health disparities, and what updated MASLD criteria mean for population-level projections.
Read clinical review